Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shamash, J.
Right arrow Articles by Oliver, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shamash, J.
Right arrow Articles by Oliver, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:169-170, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

High-dose methotrexate clearance following prior vancomycin administration: no significant interaction in the absence of overt renal impairment

J. Shamash*, S. Joel, L. Lundholm, L. Millard and T. Oliver

Department of Medical Oncology, St. Bartholomew’s Hospital, London, UK

*E-mail: brenda.bunbury@bartsandthelondon.nhs.uk

The first 10% of the full text of this article appears below.

We read with interest the clinical cases described by R. Blum et al. [1]. We are currently conducting a study into high-risk and relapsed germ-cell tumours. This protocol requires the use of high-dose methotrexate (MTX), and as we use vancomycin as part of our empirical antibiotic therapy, we have reviewed our cases for evidence of the interaction described. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?